Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Ixico PLC on Friday said it has signed a start-up agreement with a new client to provide MRI imaging services for an early phase clinical trial in multiple system atrophy, a rare nervous system condition that causes gradual damage to nerve cells in the brain.
The London-based AI data analytics company presumes a contract value of around £600,000 in early 2023 and expects the trial to last for two years.
The news comes a day after Ixico said that a client decided to discontinue a phase two trial previously announced by company. On Thursday it said it expects to suffer a reduction in anticipated revenue of £100,000 for 2023 amid a total reduction in the order book of £600,000. Financial guidance is not impacted by the cancellation, Ixico said on Thursday.
Ixico shares were 5.5% higher at 26.90 pence each on Friday morning in London, but 5.8% lower than on Monday, when they traded at 28.55p each. The stock is down 56% over the past 12 months.
By Tom Budszus, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2022 Alliance News Ltd. All Rights Reserved.